비보존 제약

082800KOSDAQ

47.0 / 100

Reference Date: 2026-10-23

Financial Score12.5 / 40

News Sentiment12.5 / 25

Momentum12.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 3.4% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Bibozen Pharmaceuticals is a specialized pharmaceutical company primarily engaged in the manufacturing and sales of prescription and over-the-counter drugs, offering a wide range of products including cardiovascular medications, diabetes treatments, and analgesics. The company operates over 190 product items through diverse business activities such as CMO, OEM, and international exports, while focusing on the research and development of innovative new drugs.

Number of Employees

292people

Average Salary

52.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

2.52Industry Average 1.200.0Point

2.1x industry avg (risky)

ROE

-36.21Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

20.79Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼380.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -16.3% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (23%)

Current 3,010Won52-week high 5,75052-week low 2,155

1-month return4.0Point

1m +3.44% (slight rise)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral전환가액의조정 (제21회차)2026-10-12
Neutral주식등의대량보유상황보고서(일반)2026-10-06